Observational studyJournal of neurology2018

Alemtuzumab as rescue therapy in a cohort of 50 relapsing-remitting MS patients with breakthrough disease on fingolimod: a multi-center observational study.

Konstantin Huhn et al.PubMed ↗Publisher ↗

No numbers read from the abstract.